

# MICROBIAL RISK AND INVESTIGATIONS



Edited by  
Karen Zink McCullough  
and Jeanne Moldenhauer

---

---

# CONTENTS

<b>I</b>	<b>INTRODUCTION</b>	<b>I</b>
	<i>Karen Zink McCullough and Jeanne Moldenhauer</i>	
	References	4
	About the Authors	4
<b>2</b>	<b>CONDUCTING MICROBIAL DEVIATIONS AND INVESTIGATIONS</b>	<b>7</b>
	<i>Frank Settineri</i>	
	Introduction	7
	Is it Real?	9
	Are Marketed Products Safe?	13
	Summary	21
	Conclusion	21
	What's the Risk?	23
	What's the Root Cause?	30
	Process flow	33
	Corrective and Preventive Actions (CAPA)	36
	CAPA Effectiveness	39
	Summary	40
	References	42
	About the Author	44

<b>3</b>	<b>PREPARING FOR AND CONDUCTING SUCCESSFUL INVESTIGATIONS</b>	<b>45</b>
	<i>Scott Sutton</i>	
	Introduction	45
	Difficulties in Phase I Microbiological Investigations	48
	Time	48
	Laboratory variability	49
	Common Mistakes in Conducting the Phase I Microbiology Investigation	51
	The red truck fallacy	52
	Testing to compliance	52
	Training to exhaustion	53
	Send the test to a competent laboratory	54
	One size fits all	55
	Preparing for a Successful Investigation	56
	The SOP system — procedures and well-designed data sheets	57
	Retains and aging plates	60
	Conducting a Successful Laboratory Investigation	60
	Preliminary laboratory data review	60
	Laboratory investigation	63
	Closing the laboratory investigation	67
	Corrective Action Plan	68
	Investigating Specific Test Failures	69
	Antimicrobial efficacy tests	69
	Bacterial endotoxin tests	70
	Environmental monitoring excursions	70
	In-process tests — raw material and pre-sterilized bulk bioburden	72
	Media fill events	73
	Microbial limits tests	73
	Sterility tests	74
	Water systems testing	74
	References	75
	About the Author	76

<b>4</b>	<b>THE MICROBIOLOGIST'S TOOL BOX</b>	<b>77</b>
	<i>Hilary Chan, Lynn Johnson, and Jill Larivee</i>	
	Introduction	77
	Risks and Consequences of Microbial Contamination in a Non-sterile manufacturing environment	78
	Anatomy of a Contamination Response Team	79
	Root cause analysis	81
	Remediation/control phase	82
	Contamination Support: What the Microbiologist Brings to the Table	83
	Trending of microorganisms	84
	Risk assessment: a microbiologist's retrospective perspective	86
	Rapid microbiological methods	88
	Be Prepared: Build your Knowledge Base for Enhanced Contamination Responsiveness	93
	What is a microbiologist's contamination control kit?	93
	Contents of a microbiologist's contamination control kit	94
	Building a base of knowledge: prospectively gathering data	99
	Practical Applications of the Microbiologist's Contamination Control Toolkit: Experimental Studies	105
	Building the study foundation: basic microbiological preparation techniques	105
	Microbial survival studies	122
	Summary	130
	References	131
	About the Authors	136
 <b>5</b>	 <b>QUALITY METRICS</b>	 <b>139</b>
	<i>Karen Zink McCullough</i>	
	Background	139
	Meaningful Metrics for Microbiological Data Deviations (MDD)	142
	Example 1 Microbiological data deviations: OOS tests	145
	Example 2 MDDs: Out of limits results	152
	Example 3 MDDs: Out of Trend (OOT) results	154
	Example 4 MDDs: invalid test results	159
	Summary	163
	References	164
	About the Author	167

## **ANTIMICROBIAL EFFECTIVENESS TESTING (AET)**

<b>6</b>	<b>ANTIMICROBIAL EFFICACY TESTING IN RISK ASSESSMENT</b>	<b>171</b>
	<i>Phil Geis</i>	
	Introduction	171
	AET	173
	Challenge microorganisms	174
	Culture	175
	Inoculum preparation	176
	Manufacturing	177
	In-Use	179
	Drugs	179
	Cosmetics	183
	Household and industrial products	185
	Summary	187
	References	188
	About the Author	198

## **OBJECTIONABLE ORGANISMS**

<b>7</b>	<b>OBJECTIONABLE ORGANISMS IN NON- STERILE PHARMACEUTICAL DRUG PRODUCTS: RISK ASSESSMENT AND ORIGINS OF CONTAMINATION</b>	<b>201</b>
	<i>David Roesti</i>	
	Introduction	201
	Evaluation of Objectionable Microorganisms in Non-Sterile Pharmaceutical Products	203
	General note	203
	Example of a procedure for evaluating microbial growth in non-sterile products	203
	Isolate characterization	207
	Isolate bioload	208
	The route of administration	210
	Nature of the product	210
	Intended recipient	211
	Trending and manufacturing process	212
	Sources of Objectionable Microorganisms	213

Personnel	214
Environment	218
Raw materials	223
Water	226
Conclusion	228
References	230
About the Author	233

## MICROBIAL LIMITS TEST

### 8 MICROBIOLOGICAL OUT-OF-SPECIFICATION AND OUT-OF-TREND INVESTIGATIONS IN NON-STERILE PHARMACEUTICAL MANUFACTURING — A CONTRACT LABORATORY PERSPECTIVE 237

*Rick Jakober*

Introduction	237
Types of OOT and OOT	240
OOS, OOT and Objectionable Microorganisms	241
Investigations	243
Case Study	251
Results and conclusion of case study	254
References	255
About the Author	257

## STERILITY TESTING

### 9 INVESTIGATING STERILITY TEST FAILURES 261

*Tim Sandle*

Introduction	261
Sterility Test Failure Investigations	262
Immediate Actions	263
Conducting Investigations	264
Test laboratory	265
Manufacturing	269
Sterility Test and Process Area Link	273
Genotypic microbial identification	274
Re-testing the Finished Product Batch	274

Concluding Sterility Test Failure Investigations	275
Product Impact Assessment	276
Conclusion	278
References	279
Appendix: Sterility Test Failure Investigation Checklist	281
About the Author	288

## **10 CONDUCTING STERILITY TEST INVESTIGATIONS USING THE FDA MODEL 291**

*Jeanne Moldenhauer*

Introduction	291
Sterility Testing Methods	292
Compendial Guidance on Sterility Test Investigations	293
FDA Guidance on Sterility Test Investigations	294
When a Sterility Test Failure is Identified	295
Procedures for Conducting the Investigation	296
Assessing the Validity of the Sterility Test Result	297
Conducting the Investigation	298
Identification of the sterility test contaminant	299
Review of laboratory test results and deviations	300
Microbial monitoring of the production area environment	302
Microbial monitoring of personnel	305
Product presterilization bioburden evaluation	305
Production records review	305
Review of the manufacturing history	306
Product Impact Analysis	306
Concluding the Investigation	307
Determining the Final Product Disposition	308
References	308
About the Author	309

## **ENVIRONMENTAL MONITORING**

## **11 DETERMINING THE PRODUCT RISK WHEN CONTAMINATION OCCURS IN ENVIRONMENTAL MONITORING 313**

*Jeanne Moldenhauer*

Introduction	313
Investigation Expectations	314

Risk Assessments	315
Other Concerns with Contamination Events	321
The production of toxins	321
Closely related organisms	322
How much contamination is too much	322
Inability to identify the contaminant	322
Changes to Bergey's Manual	324
The Problem of "Ones"	324
Conclusion	325
References	325
About the Author	326

## **12 LEVERING RISK ASSESSMENTS IN ENVIRONMENTAL MONITORING INVESTIGATIONS 327**

*Karen Ginsbury*

Introduction	327
Risk Management and the Quality System	329
The PA in CAPA	329
The Environmental Control Program — Proactive Quality Management	333
The environmental control strategy — "plan" of P-D-C-A cycle	
Risk mitigation and communication	333
Environmental Monitoring — Proactive Quality Management	334
"Check" of P-D-C-A cycle	334
Data Trending	338
Microbiological Data Deviations and Environmental Monitoring Excursions	339
Investigations: problem solving cycle	
The CA in CAPA	339
Knowledge Management and Lessons Learned	361
Updating the risk assessment post investigation and improving the control strategy	
More PA in CAPA	361
References	364
About the Author	364

<b>13</b>	<b>MICROBIAL INVESTIGATION CASE STUDIES</b>	<b>365</b>
	<i>Ken Muhvich</i>	
	Introduction	365
	Background	366
	Case Studies — Failures to React to Environmental Monitoring Excursions	370
	Case study #1 — Batch sterility failure	370
	Case study #2 — Batch sterility failure	371
	Case study #3 — Critical surface sample excursion	372
	Case study #4 — False-positive sterility tests	373
	Case study #5 — Batch sterility failure	374
	Case study #6 — Sterility test failure	375
	Case study #7 — Environmental monitoring excursions	377
	Case study #8 — Environmental monitoring excursions	378
	Case study #9 — Bulk solution bioburden excursion	379
	Case study #10 — Over action environmental data excursion	381
	Analysis of EM Results — Important Questions to Answer	382
	References	383
	About the Author	384
 <b>14</b>	 <b>ASSESSMENT OF ENVIRONMENTAL MONITORING DATA IN SUPPORT OF ASEPTIC MANUFACTURING</b>	 <b>385</b>
	<i>Veronica Marshall, David Correal, Mulyadi Setiawan and Karen Zink McCullough</i>	
	Introduction	385
	Current Environmental Monitoring Guidances: Viables	387
	Data	389
	The Dilemma	392
	Patterns of contamination	393
	Contamination recovery rates	396
	A Possible Compromise Program	399
	Investigations	401
	Summary	409
	References	409
	About the Authors	410

<b>15 INVESTIGATIONS FOR PERSONNEL MONITORING</b>	<b>413</b>
<i>Anne Marie Dixon</i>	
Background	413
Qualification	415
Case Study #1	416
Exit monitoring	419
Case Study #2	419
Contamination Investigations — Cleanroom	422
Case Study #3	422
Test protocol	424
Walking	426
Sit/stand	429
Door entrance	431
Waist turning activity	434
Curtain entrance	436
Summary of case study #3	439
Summary	440
References	440
About the Author	441
 <b>16 REAL-TIME RISK ASSESSMENT CONTROL STRATEGY</b>	 <b>443</b>
<i>Sean Toler</i>	
Real-time Risk Assessment Shaped from Quality by Design	443
QbD Risk Assessments to Develop RTRA	446
QbD Design Space Impact on RTRA	449
QbD Control Strategy of RTRA	449
Continuous Improvement from RTRA	454
Implementing the RTRA	458
Microbiologist Development for RTRA	471
Cultural Improvement from RTRA	474
Summary	475
References	476
About the Author	256
 <b>17 MOLD CONTAMINATION</b>	 <b>481</b>
<i>Brian G. Hubka and Jeanne Moldenhauer</i>	
Introduction	481
What is the Concern with Mold Contamination?	483

Pathogenicity	483
Mycotoxin production	484
Allergic reactions	485
Invasiveness of mold	486
Criteria for mold growth	486
Damaging effects of mold	488
Expectations for cleanrooms	488
Other health concerns	488
Examples of Mold Contamination Events	489
The New England Compounding Center (NECC)	489
Warning Letter CBER-12-07	491
Warning Letter 13-ATL-17	491
Warning Letter WL-320-14-13	492
Microbial contamination of syringes	493
Conducting the Investigation	493
Investigating environmental monitoring excursions	494
Specific Considerations in Looking for Mold Contamination	496
Facilities	496
Equipment surfaces	497
HVAC equipment and performance	498
Airflows and pressurization	498
Environmental considerations	498
Cold storage areas	498
Gowning and changing areas	499
Hidden molds	499
Other contaminated surfaces	499
Supplies	499
Corrective Actions	500
Changing from Corrective Actions to Preventative Actions	501
Conclusion	502
References	502
About the Authors	504
 <b>18 MICROBIAL EXCURSIONS IN CLEANROOMS</b>	 <b>507</b>
<i>Jim Polarine and Carol Bartnett</i>	
Introduction	507
Cleanroom Monitoring	508
Non-viable monitoring	509
Viable monitoring	510
Causes of Microbial Excursions	512
Personnel and practices	512

Facility design and condition	516
Cleaning and disinfection	520
Equipment/raw materials/consumables transfer (ingress)	525
Investigating Microbial Excursions	528
Conclusion	533
References	534
About the Authors	538

## MEDIA FILLS

<b>19 FAILURE INVESTIGATIONS IN RESPONSE TO ADVERSE ASEPTIC FILLING SIMULATION RESULTS</b>	<b>541</b>
<i>Tony Cundell</i>	
Introduction	541
Industry Practice	542
Regulatory Guidance	542
Evolution of the Media Fill Acceptance Criteria	549
Patterns of Microbiological Growth in Soybean Casein Digest Medium	550
Patterns of the Turbid Vial Distribution Within the Media Fill	551
Laboratory Investigations of Turbid Vials	552
Origin of Microorganisms Isolated from Failed Media Fills	553
Implications of the Human Microbiome Project to Pharmaceutical Microbiology	553
Manufacturing Investigations of Turbid Vials	555
Conclusions	557
References	557
About the Author	559

## ENDOTOXIN INVESTIGATIONS

<b>20 INVESTIGATION OF ENDOTOXIN OUT-OF-SPECIFICATION AND UNEXPECTED RESULTS</b>	<b>563</b>
<i>James F. Cooper</i>	
Overview	563
Pyrogen Outbreaks of the Past	564
Pyrogenic outbreak related to Active Pharmaceutical Ingredient (API)	565

Endotoxin OOS related to equipment and sampling	567
Aseptic meningitis from contaminated intrathecal drug	567
Endotoxin OOS caused by faulty component	568
Errant positive BET on surgical eye solution	569
Results that are not Definable as an OOS Event	569
Hot well	570
Glucan interference	570
Low LPS recovery	571
Non-robust kinetic BET conditions	572
Robust Kinetic BET Conditions Minimize Investigations	572
Summary	573
References	575
About the Author	577

WATER SYSTEMS

21 INVESTIGATION OF MICROBIOLOGICAL EXCURSIONS DURING A WATER SYSTEM VALIDATION	581
<i>Karen Zink McCullough</i>	
The Company	582
The Product	582
The Company's User Requirement Specification for "Clean Water"	582
The System	583
The Validation Strategy	585
PQ Phase 1 (PQ-1)	585
PQ Phase 2 (PQ-2)	586
PQ Phase 3 (PQ-3)	586
The Data	587
The Investigation Strategy	590
The bones	591
Sanitization	591
Sampling and sampling containers	592
Testing	593
Water quality	594
Hardware	595
Assessment	596
Conclusion	597
References	598
About the Author	598

## PARTICULATES

<b>22 PARTICULATE MATTER IN INJECTABLE DRUG PRODUCTS</b>	<b>601</b>
<i>Stephen E. Langille</i>	
Introduction	601
Classification and Sources of Particulate Matter	602
Clinical Effects of Injected Particulate Matter	605
Route of administration	606
Size and shape	607
Number	610
Composition	611
Patient population	615
Relevant Regulations and Standards	617
Continuing Efforts	623
Conclusion	624
References	625

## MICROBIAL IDENTIFICATIONS

<b>23 INVESTIGATING MICROBIAL IDENTIFICATION RESULTS</b>	<b>639</b>
<i>Jeanne Moldenhauer</i>	
Background on Microbial Identifications	640
Selecting the System for Use	641
How to Distinguish between Systems for Specific Types of Organisms	645
Taxonomic Issues	647
Typical Problems in Identifications	650
Organism preparation for testing	651
Use of similarity numbers	652
Phenotypic methods	652
RiboPrinter® methods	652
Verification of microbial identification methods	654
Difficulties in identification	654
Making the right assumptions	655
Conclusions	655
References	655
About the Author	658

**STERILIZATION SUPPORT**

<b>24 ADDRESSING DEVIATIONS IN BIOLOGICAL INDICATOR POPULATION COUNTS AND D-VALUE ANALYSIS</b>	<b>671</b>
<i>Jeanne Moldenhauer and I.J. Pflug</i>	
Introduction	671
Regulatory expectations for microbial count and resistance testing	673
United States Pharmacopeia (USP) Compendial requirements	674
Other guidance documents	675
Deviations in Confirmation of Enumeration (Population) counts	676
Performing D-Value Analysis	678
Deviations when Confirming D-Values	680
Use of a qualified laboratory	681
Qualified personnel	683
Verification of microbial counts	683
Verification of resistance values	683
Equipment comparisons	684
Qualification of media	684
Media supplements	685
pH	685
Organism strain, type and purity	685
Heat resistance test method reviews	686
Shipping conditions	687
Technical information packs	687
Conclusion	687
References	688
About the Author	691
Appendix: The D-Value in 2003, and some of its History	692
History of the D-Value	692
General Comments about the D-Value	694
Application of the D-Value Concepts to Other Systems such as Ethylene Oxide, Hydrogen Peroxide, Low-Temperature Steam Formaldehyde, Radiation, etc.	696
Hydrogen Peroxide	697
Literature Cited	699

## **25 INVESTIGATING POSITIVE BIOLOGICAL INDICATORS OR INSUFFICIENT KILL OF INDICATORS IN STERILIZATION STUDIES 701**

*Jeanne Moldenhauer*

Background	702
Biological indicators	702
Regulatory actions taken for BIs	705
Useful Tasks Prior to the Actual Testing of the BIs	706
Sterilization Modeling and how it can be used with Investigations	708
Dry heat sterilization	710
Gas sterilization	712
Radiation sterilization	712
Survivor and kill time evaluations	713
Considerations when a BI does not Yield the Expected Results	714
Calculation of the probability of a positive BI	714
Ensuring the BI challenge is appropriate for the process	716
Failure to Deliver the Sterilization Process to the BI	717
Moist heat	717
Gas sterilization cycles	720
Vapor sterilization cycles	720
BI Heat Resistance is Affected by Substrates	720
Resolving Issues in the Verification of Performance Standards	721
Discrepancies in the enumeration of population (control) counts	721
Discrepancies in thermal death time analysis (D-value)	723
Other Considerations for Recovery of Aberrant BI Results	724
Steam traps	724
Other typical investigation parameters	724
Conclusion	725
References	725
About the Author	729

## **RAPID METHODS**

## **26 CONDUCTING INVESTIGATIONS RAPID MICROBIOLOGY METHODS 733**

*Jeanne Moldenhauer*

Introduction	733
Rapid Methods — Why use them?	733
Automated Methods	735

Using Rapid Microbiological Methods to aid in	
Conducting Investigations	735
Narrowing Down Areas of Contamination	736
Case study	736
Case study	737
Evaluating the Effectiveness of Corrective Actions	737
Case study	737
Personel Gowning and Aseptic Behavior	738
Identification of Microorganisms	738
Conducting Investigations for Issues with RMMs	739
Case study	739
Where do you Start when the Results Indicate Contamination?	740
Typical Microbiological Investigations	741
Viability Methods	742
Case study	743
Higher counts	744
Case study	744
Viability Based Methods not Recovering all Organisms	745
Inability to Identify Microorganisms from the Contaminant	745
Laser Based Systems	746
Growth-Based Technologies	746
Sterility Investigations	747
General Issues with RMM Equipment	747
Contamination of RMM Equipment	747
Conclusion	748
References	748
About the Author	749

## **CONTAMINATION RISK EVALUATION**

<b>27</b>	<b>CONTAMINATION RISKS AND THE PATIENT</b>	<b>753</b>
	<i>Mark Hunter, Michelle Luebke, and Mark Pasmore</i>	
	Patient 1	754
	Patient 2	754
	Infection	755
	Sepsis	757
	Signs and symptoms of infection/sepsis	758
	Patient risk factors	761
	Infection/sepsis: the perfect storm	765
	Investigation: the causal continuum	767
	Intrinsic continuum	769

Extrinsic continuum	770
Manufacturing contamination impacts on patients	776
Microbial Contamination in the Manufacturing Environment	777
Non-sterile, terminally sterilized, aseptically filled	779
Proliferation	781
Ingress	781
Biofilms as an elevated risk	782
Conclusions	783
References	784
About the Authors	790
 <b>28 CONTAMINATION CONTROL RISK ASSESSMENT</b>	 <b>793</b>
<i>Tim Sandle</i>	
Introduction	793
Sources of Contamination	796
The Regulatory Focus on Quality Risk Management	798
Objectives of Risk Assessment and Risk Management:	
The Key Concepts	800
Contamination Control Risk Assessment	803
Methods for prospective risk assessments	803
Simple risk assessment tools	811
Assessing retrospective contamination events	828
Conclusion	841
References	842
About the Author	845
 Index	 847